All riders participating in the Tour de France underwent doping tests on the rest day Monday, according to the International Testing Agency (ITA) on Wednesday. Several teams, including Red Bull-Bora-Hansgrohe, which includes Belgian Olympic champion Remco Evenepoel, announced that their riders were tested on Tuesday. This came after controversial tests conducted in the early hours of Sunday targeting Slovenian race leader Tadej Pogačar and Danish main rival Jonas Vingegaard, noting that the latter withdrew from the Tour following a crash, hours after being woken at 2:00 a.m. by anti-doping inspectors. The International Testing Agency said in a late Tuesday statement: 'The International Testing Agency, ITA, confirms the implementation of a comprehensive blood sampling campaign within the framework of the Athlete Biological Passport (ABP) during the rest day of the Tour de France on July 20, 2026.' It added: 'The testing campaign included all riders in the race, as part of the Agency's ongoing anti-doping program based on intelligence gathering and risk assessment during the race.' The ITA did not disclose any results, and a spokesperson said processing the results would take weeks. The Agency explained that the Athlete Biological Passport does not aim to directly detect a prohibited substance or method, but monitors specific biological variables over time to detect changes that may indicate effects of doping. A number of riders, including Pogačar and Evenepoel, described the nighttime tests as inhumane and a lack of respect for athletes. The Professional Riders Association (CPA) also criticized these measures, saying they could negatively affect riders' rest and recovery between the demanding stages of the Tour de France.